P-1218. Assessment of Cefepime-Taniborbactam (FEP-TAN) Transmembrane Clearance (CLTM) in an Ex vivo Continuous Renal Replacement Therapy (CRRT) Modeldoi:10.1093/ofid/ofae631.1400BACKGROUND. Optimal antibiotic dosing in patients undergoing CRRT is influenced by many factors that affect drug ...
Taniborbactam (TAN; VNRX-5133) is a novel bicyclic boronic acid 尾-lactamase inhibitor (BLI) being developed in combination with cefepime (FEP). TAN inhibits both serine and some metallo-尾-lactamases. Previously, the substitution R228L in VIM-24 was shown to increase activity against oxy...
In complicated UTIs, cefepime–taniborbactam increased treatment success vs. meropenem at 19 to 23 dAuthordoi:10.7326/ANNALS-24-00447-JCBruno Granwehr, MD, MSAnnals of Internal Medicine